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Abstract
Object: Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions
through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark
glioma tissue a fluorescent tracer must have the ability to penetrate through the blood brain barrier (BBB) and provide
delineation in the tumor periphery where heterogeneously intact BBB may exist. In this study it was hypothesized that, due
to its smaller size, fluorescently labeled anti-EGFR Affibody protein (,7 kDa) would provide a more clear delineation of the
tumor margin than would fluorescently labeled cetuximab, a full antibody (,150 kDa) to the epidermal growth factor
receptor (EGFR).
Methods: Cetuximab and anti-EGFR targeted Affibody were conjugated to two different fluorescent dyes (both emitting in
the near-infrared) and injected intravenously into 6 athymic mice which were inoculated orthotopically with green
fluorescent protein (GFP) expressing human U251 glioma cells. Each mouse was sacrificed at 1-h post injection, at which
time brains were removed, snap frozen, sectioned and quantitatively analyzed for fluorescence distribution.
Results: Ex vivo analysis showed on average, nearly equal concentrations of cetuximab and Affibody within the tumor (on
average Affibody made up 4966% of injected protein), however, the cetuximab was more confined to the center of the
tumor with Affibody showing significantly higher concentrations at the tumor periphery (on average Affibody made up
72615% of injected protein in the outer 50 um of the tumor). Further ex vivo analysis of detection studies showed that the
Affibody provided superior discrimination for differentiation of tumor from surrounding normal brain.
Conclusions: The present study indicates that fluorescently labeled anti-EGFR Affibody can provide significantly better
delineation of tumor margins than a fluorescently labeled anti-EGFR antibody and shows considerable potential for guiding
margin detection during neurosurgery.
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Introduction
Fluorescence imaging technology may have its greatest clinical
potential in the rapidly expanding field of fluorescence-guided
neurosurgery. [1–6] The key to fluorescence guided surgical
oncology is the ability to create specific contrast between normal
and glioma tissue. This, together with a fluorescence-enabled
surgical microscope, allows removal of molecular-defined portion
of the tumor while at the same time minimizing removal of normal
brain. The prognosis of patients suffering from malignant gliomas
has been linked to the completeness of tumor removal and the
ability to selectively mark tumor tissue with fluorescence has
already shown promise to improve outcomes through reduced
margins in surgical resection. [7–9] In this study, two potential
fluorescent cellular receptor targeting agents of different size are
compared in terms of their ability to mark the outer regions of
glioma tumors. The hypothesis tested here is that smaller binding
agents would better define the infiltrative edge of the tumor.
Fluorescent contrast enhancement of malignant gliomas was
first reported on in 1948 by Moore et al. where an injection of
fluorescein was preferentially taken up by the tumor compared
to the normal brain tissue as a result of the tumor’s disrupted
blood brain barrier (BBB). [10] While the use of fluorescein
continues to be examined today, [11] the preponderance of
research in the area of fluorescence guided surgery has focused
on the administration of 5-aminolevulinic acid (5-ALA), a
natural precursor of protoporphyrin IX (PpIX) in the heme
biosynthesis pathway. [12,13] PpIX is selectively synthesized in
high grade glioma, with normal brain having extremely low
concentrations [14,15] and the resulting fluorescence contrast
has been used to reduce margins in surgical resection. [8,16]
This approach, however, is not without its limitations and one
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of the primary is that its maximal useful signal seems to be
restricted to high grade gliomas [17,18].
One promising yet little explored method for differentiating
tumor from normal brain tissue in surgical resection is the
administration of fluorescently labeled targeted proteins. An
important advantage of this over the simple administration of
untargeted fluorescent tracers such as fluorescein or indocyanine
green [19] is that it could provide specificity through the targeting
of overexpressed glioma cell surface receptors. Contrast with this
approach is governed largely by receptor-ligand affinity and
receptor density rather than cellular metabolism as is the case in
PpIX approaches [12,14,15] and as a result targeted fluorescence
imaging will not suffer from the problem of reduced PpIX
production encountered in low-grade gliomas. However, this
approach is not without its own unique problems, one of which is
the difficulty in establishing receptor status prior to any initial
surgery. It must also be pointed out that the tumor used in the
present study, U251, is fact a high grade glioma and any specific
problems associated with low grade gliomas and the use of
targeted fluorescent probes will not be seen in this study. Another
concern with the approach used is that the dye-protein conjugates,
which are much larger than 5-ALA or fluorescein, may be too
large to adequately penetrate tumor areas with a partially intact
BBB and we must keep in mind that breakdown of the BBB is less
pronounced in low grade gliomas.
The BBB generally limits delivery of imaging agents to the
normal brain, but in tumors this is typically compromised to an
extent that allows for sufficient contrast in imaging of the bulk
tumor. One area of concern, however, is that BBB breakdown is
often incomplete, particularly in newly formed areas of growth
including micro-invasive regions. [20–22] The result is that
exogenously administered agents tend to accumulate in the tumor
interior where breakdown of the BBB is most complete, but not
necessarily in the infiltrative edges where the BBB more closely
resembles that of the normal brain. [21–23] Delivery to these areas
is of the utmost importance if these methods are to achieve clinical
success.
As a preliminary investigation into this area, the present study
compares delivery of two promising targeted proteins – a full
antibody and an Affibody, which have substantial differences in
size and target affinity to orthotopic human gliomas grown in a
murine model. The proteins are targeted to epidermal growth
factor receptor (EGFR), a cell-surface receptor that is over-
expressed in many human gliomas [24,25] However, it must be
noted that EGFR is rarely over-expressed in low grade diffuse
gliomas and this prevents it from being an optimal target for
marking this type of tumor. While low grade diffuse gliomas
present the most difficult category to treat they are not the only
type of glioma that could benefit from improvements in
fluorescence contrast. High grade gliomas for which PpIX
fluorescence is most well suited may also benefit from the use of
targeted fluorescent probes possibly as a tool to be used in
combination with PpIX. Additionally, as more promising targets
on low grade gliomas are elucidated, the present work may help
to inform the development and testing of targeted proteins for
these receptors. Integrin avb3 is one such cell surface receptor
that has already been shown to be overexpressed on low grade
gliomas. [26] In the present study, the penetration of the two
proteins to the center and periphery of tumors was examined by
fluorescent imaging of ex vivo brain slices collected from mice
1 h after intravenous injection of the fluorescently labeled
proteins.
Materials and Methods
2.1 Protein Labeling
The smaller of the two proteins used to target EGFR, anti-
EGFR Affibody (Affibody AB, Solna, Sweden), was diluted with
phosphate buffered saline (PBS) at pH 7.5 to achieve a concen-
tration of 1 mg/ml. As per the manufacturer’s recommendations,
the Affibody molecules were reduced by adding dithiothreitol
(DTT, mM) and incubated on a magnetic stirrer for two hours at
room temperature. Excess DTT was removed by passage through
a polyachrylamide 6000 desalting column (Thermo Scientific,
Rockford, IL). Recovered protein was concentrated in a centrifuge
using a 6 kDa molecular weight cutoff (MWCO) column (GE
Vivaspin 2,Pittsburgh, PA). At this point the Affibody was ready
for binding with a fluorophore. The fluorophore, IRDye 800CW
maleimide (LI-COR Biosciences, Lincoln, Nebraska), was sus-
pended in pure water at approximately 2 mg/ml, and was added
to the protein solution to achieve a 2.5 molar excess of dye to
protein as recommended by LI-COR. The Affibody-IRDye
800CW solution was then incubated on a magnetic stirrer for
approximately two hours at room temperature, excess dye was
removed by passage through a desalting column, and concentrated
in the centrifuge using a 6 kDa MWCO column. A dilution made
from the concentrated labeled Affibody solution was examined in
a UV-Vis spectrophotometer (Cary 50 BIO UV-Visable spectro-
photometer, Varian, Palo Alto, CA) to record the absorption
spectrum from 220–800 nm. Protein concentrations and dye-to-
protein ratios were determined using absorption values at 280 nm
and 780 nm as described by LI-COR. All labeled Affibody
solutions yielded dye-to-protein ratios between 0.65 and 0.73.
The larger of the two EGFR-targeted proteins, cetuximab
(ImClone Systems, Inc, NewYork, NY) was labeled with the
fluorophore, IRDye 680RD NHS ester (LI-COR). 2 mg/ml of the
cetuximab was added to a 5-mg/ml solution of the fluorophore
suspended in DMSO to achieve a 3 molar excess of dye to protein
as recommended by LI-COR. The cetuximab-IRDye 680RD
solution was incubated on a magnetic stirrer for approximately
two hours at room temperature. Excess dye was removed by
passage through a polyachrylamide 6000 desalting column. The
labeled protein solution was then concentrated in a centrifuge
within a 50-kDa MWCO column (GE Vivaspin 2, Pittsburgh, PA).
The absorption spectrum of the labeled cetuximab was recorded
from 220–700 nm using the UV-Vis spectrophotometer to
measure concentrations and dye-to-protein ratios (dye-to-protein
ratios were between 1.74 and 1.87).
For all animal injections, cetuximab-IRDye680RD and Affi-
body-IRDye800CW are mixed together and injected simulta-
neously. In order to rule out the possibility of binding between the
two proteins, the Octet Red 96 (forteBIO, Menlo Park, CA) which
uses biolayer interferometry to identify molecular binding, was
employed. Cetuximab-IRDye680RD was captured on Protein A.
Affibody-IRDye800CW was diluted to the same concentration
used for all injections (0.05 uM) and allowed to mix with the
immobilized cetuximab_IRDye680RD for approximately thirty
minutes. No binding between the proteins was seen.
2.2 Animal Models
All animals were used in accordance with an approved protocol
and the policies of the Institutional Animal Care and Use
Committee (IACUC) at Dartmouth College. Twenty-six, six-
week-old female nude mice were obtained from Charles River
Laboratories (Wilmington, MA) and randomly separated into
three experimental groups. Fourteen animals were used in a
plasma excretion study and the remaining twelve animals were
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inoculated with orthotopic implantations of human glioma cell
line, and either injected with a mixture of the two EGFR-targeted
tracers (n=6) or used as naive controls (n=6).
A green fluorescent protein (GFP) expressing human neuronal
glioblastoma cell line, U251-GFP (supplied from Dr. Mark Israel,
Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical
Center and transfected with GFP in our lab), was selected for
implantation because it is a cell line known to express moderate
levels of the targeted receptor, EGFR. [27,28] Implantations were
carried out under anesthesia (90:10 mg/kg ketamine:xylazine). A
small incision was made in the scalp, exposing the landmarks on
the skull, and a 1-mm rotary drill was used to create an access to
the brain, 2 mm behind the bregma and 2 mm to the left of the
midline. 56105 U251-GFP cells were injected at a 2 mm depth
into the left cerebral hemisphere of the mice using in 5 uL of
phosphate-buffered saline (PBS) using a Hamilton syringe
(Hamilton Company, Reno, NV), guided by a non-digital
stereotaxic frame fitted with tubing to allow isoflurane anesthesia
(Stoelting Co, Wood Dale, IL). Based on the atlas of the adult
mouse brain this places the tumor in the area of the dorsal nucleus
of lateral geniculate body. [29] The cells were injected over a 5-
minute period, after which the needle was slowly retracted from
the brain. Bone wax (Ethicon, Inc, Piscataway, NJ) was used to
close the hole in the skull while the incision in the scalp was closed
using Vetbond (J.A. Webster, Inc, Sterling, MA) [30–32].
One week following tumor implantation, mice were placed on a
non-fluorescent diet (Purified Mouse Diet, CAT NO. 904606,
from MP Biomedicals, LLC, Illkirch, France) and tumors were
allowed to grow for two further weeks before carrying out
fluorescent tracer experiments.
2.3 Plasma Clearance
The plasma excretion rates of cetuximab-IRDye680RD and
anti-EGFR Affibody-IRDye800CW were determined by moni-
toring the fluorescence in mouse blood for 24 h following
intravenous injection of a mixture containing between 0.1 and
0.75 nmols of each protein tracers. At selected time points (all mice
at 1 min and then at three additional time points within 24 h),
approximately 150 mL of blood was collected via a submandibular
bleeding technique using a 5 mm lancet (Goldenrod; MEDIpoint,
Mineola, NY) into a vial previously rinsed with Heparin (Hospira,
Lakeforest, IL). Three mice had pre-injection blood samples
collected to enable determination of the autofluorescence
spectrum. The blood samples were centrifuged and the resulting
plasma layer removed for analysis on a fluorimeter (Fluoromax-3,
Horiba Jobin Yvon, Edison, NJ). Cetuximab-IRDye680RD was
analyzed using an excitation of 620 nm over an emission range of
650–800 nm while anti-EGFR Affibody-IRDye800CW was ana-
lyzed using an excitation 720 nm over an emission range of 730–
900 nm. The baseline of each fluorescence spectra was determined
by fitting a fourth degree polynomial and baselines were then
subtracted from the spectra. The resulting spectra were then
integrated over 10 nm at the fluorescent peaks. Autofluorescence
was determined in the same manner using the pre-injection
samples and the average integrated signal for autofluorescence was
then subtracted from each sample. The 1 min post-injection blood
sample was used to normalize fluorescence intensities and the
resulting data was then fit to a bi-exponential decay. All
calculations were performed using Matlab 2009a (Mathworks,
Natick, MA) [33,34].
2.4 Tracer Uptake in Tumor
To determine the relative uptakes of the cetuximab and
Affibody based EGFR-targeted tracers in an EGFR-expressing
glioma, 0.1 nmol of each tracer was simultaneously injected
intravenously into six of the twelve mice implanted with U251-
GFP tumors. At 1 h post injection mice were euthanized by
cervical dislocation under ketamine-xylazine (90:10 mg/kg i.p.)
anesthesia. The 1- h time point was chosen for its potential future
clinical feasibility in guiding surgical resection. Brains were
extracted, covered in optimum cutting temperature (OCT)
medium (Tissue TekH, Sakura Finetek USA, Inc., Torrance,
CA), snap frozen at 260uC in methylbutane and dry ice, and
stored at 280uC until used for sectioning. The six control mice
were treated the same as the others except that they were not
injected with the cetuximab and Affibody. This provided a means
of investigating the level of autofluorescence in tumor and normal
brain tissue (i.e., fluorescence in the absence of any injected dyes).
One mouse from the group injected with the two proteins failed to
grow an observable tumor, leaving five mice in that group.
2.5 Tissue Sectioning and Imaging
Tissue sections (10 mm in thickness) were prepared on a
cryotome (CM 1850, Leica Microsystems, Richmond, IL), placed
on glass slides (Precleaned Gold Seal Rite-on Micro Slides, Gold
Seal Products, Portsmouth, NH) and stored at 280uC. Fluores-
cence from GFP in the frozen sections was imaged on the
Typhoon 9410 Variable Mode Imager (GE Healthcare, Milwau-
kee, WI) at 25 micron resolution (488 nm excitation, emission at
500–540 nm). Comparison of GFP-expression with a sampling of
adjacent hematoxylin and eosin (H&E) stained tissue sections
confirmed that GFP signal accurately outlined tumor regions.
Tissue sections were then scanned on the Odyssey Infrared
Imaging System (LI-COR Biosciences) at 21 mm resolution with a
gain of 9.0 selected in both the 700 and 800 nm channels. These
settings provided adequate signal without saturation, allowing for
the quantification of the level of the cetuximab and Affibody
tracers. Between thirty and sixty tissue slices were examined from
each mouse.
2.6 Protein Concentration Quantification
Protein concentrations at the tumor edge, tumor interior and
over the whole tumor were quantified from Odyssey fluorescence
images using the following equation:
protein½ x~
Fx{Ax
calx:DPx
where Fx represents fluorescence of the select region at x = 700 nm
or x= 800 nm for the cetuximab and Affibody tracers, respective-
ly; Axis the average autofluorescent level at 700 or 800 nm
measured from the uninjected brain slices in the corresponding
region (tumor edge, tumor interior or whole tumor); DPx is the
dye-to-protein ratio of the corresponding tracer; and calx is a
fluorescence to dye concentration calibration factor for the each
tracer. The calibration factors for the two tracers were determined
by carrying out serial dilution experiments on Odyssey system.
2.7 Image Analysis
The Odyssey fluorescence images were scaled using bicubic
interpolation to produce the same 25 mm pixel size recorded using
the Typhoon. All three sets of images were then aligned using a
combination of manual point selection and automated cross
correlation in Matlab R2009a (Mathworks, Natick, MA). Approx-
imately one out of every ten slides was viewed using ImageJ
(National Institute of Health) to verify coregistration accuracy.
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Tumor segmentation was carried out using a GFP threshold;
i.e., all pixels having a GFP signal greater than three standard
deviations above the mean of the contralateral region were
regarded as tumor and all those below being regarded as normal
brain. The outer two pixels or 50 um of each tumor was defined as
the tumor edge while the tumor interior was defined as the region
more than five pixels or 125 um from the actual tumor edge. Only
continuous regions of tumor with areas greater than 0.625 mm2
were used in this sub-analysis.
2.8 Statistical Analysis
For comparison purposes the means and standard deviations of
the signals at both channels were calculated for each examined
region as well as for all metrics used. These are reported as: mean
6 standard deviation, throughout the manuscript.
Statistical analysis was performed using R version 2.15.1 from
the R foundation for statistical computing. Welch Two Sample t-
tests were performed to determine statistical significance in the
parameters related to differences in signal from the Affibody and
cetuximab channels in different regions of the tumor for the five
protein injected animals. These parameters included the difference
in Affibody protein fraction between the tumor interior and tumor
edge as well as the differences in signal decrease from the tumor
interior to the tumor edge for the two channels. A Welch Two
Sample t-test was also used to determine the statistical significance
of the difference in signal between the tumor regions and the
contralateral regions in the non-injected control animals at both
the 700 and 800 nm channels.
Results
Fig. 1. shows the GFP outlined tumor, H&E staining of the
same tissue section and raw fluorescence at both the Affibody and
cetuximab channels. The most striking observation of the Affibody
and cetuximab maps is that on average cetuximab appears to be
more confined to tumor interiors (Fig. 1D), while the Affibody
appears more evenly dispersed throughout the tumor (Fig. 1E).
Maps of the percentage of signal from the Affibody channel
(Affibody fluorescence/(Affibody fluorescence+cetuximab fluores-
cence)) reinforced this observation, illustrating a clear increase in
Affibody at the tumor margins compared to cetuximab (Fig. 1F).
Control mice that received tumor implantations but no protein
injections were used to determine background tissue signals.
Tumor autofluorescence proved to be significantly higher than the
autofluorescence in the brain tissue at both the 700 and 800 nm
channels.(p=0.011 and p=0.005, respectively). This is demon-
strated by the ability to localize the tumor somewhat based on
autofluorescence alone at both channels (Fig. 2D & 2E).
Autofluorescence signal was found to be most pronounced at the
tumor interiors and lowest at tumor edges, with a fluorescence
level of 12036132 and 610631 in the tumor margin and
14246284 and 691683 in the tumor interior for the 700 and
800 nm channels, respectively. The fraction of signal from the
800 nm channel, which can be contrasted with the Affibody
fraction image seen for an injected animal in Fig. 1F, did not show
any spatial pattern between tumor interior, tumor edge, or
surrounding tissue (Fig. 2F).
The apparent spatial differences in Affibody and cetuximab
uptake in the tumors (i.e., that the Affibody appeared to penetrate
the margins of the tumors better than the cetuximab) were
quantified by dividing the signal from each tumor into an edge
region and an interior region as described in the Materials and
Methods section. A graphic illustration of this delineation is
presented in Fig. 3, where both the tumor edge (Fig. 3B) and
tumor interior (Fig. 3C) masks are shown alongside the entire
segmented tumor (Fig. 3A). Raw signals from these regions as well
as from a contralateral region were collected from all five injected
animals, as well as the six control animals and are plotted in Fig. 4.
This analysis demonstrates that the signal from both tracers
decreased from the tumor interior to the tumor edge, however, the
decrease was significantly larger for the cetuximab tracer for which
signal dropped an average of 5065% vs. the Affibody tracer for
which signal dropped only 3167% (p=0.002).
The conversion from raw signal to estimated protein concen-
tration allowed delivery of the proteins to different regions of the
tumor to be compared. In order to quantify this comparison the
concentration of Affibody as a percentage of total protein
concentration was determined for each region of the tumor. The
results can be seen in Fig. 5. While on average the overall delivery
of Affibody to the tumor was nearly identical to that of cetuximab,
there was a distinct increase in the Affibody protein fraction in the
tumor edge compared to the tumor interior. This increase was
observed in all animals and ranged from approximately 40% to
65%. On average the percentage of Affibody to total protein in the
tumor interior was only 4565%, while at the tumor edge the
fraction of Affibody was 72611%. (p = 0.003).
To fully understand the delivery characteristics of both tracers,
plasma excretion curves were measured for both cetuximab-
IRDye 680RD and anti-EGFR Affibody-IRDye 800CW and a bi-
exponential decay equation was fit to the data (Fig. 6). [35,36] The
plasma clearance for cetuximab was found to be significantly
slower than for the Affibody with decay constants of 0.03 min21
and 0.0003 min21 for the cetuximab clearance, compared to
0.05 min21 and 0.002 min21 for the Affibody clearance. At the
1 h time point of interest in this study approximately 66615% of
the Affibody present one minute following injection was cleared
from the blood, while only 37624% of the cetuximab present one
minute following injection was cleared from the blood.
Discussion
The injection of fluorescent tracers targeted to molecular
receptors over-expressed in tumors, such as EGFR, provide a
promising means of improving tumor contrast during surgical
resection. The great potential of tumor receptor targeting for both
diagnostic and therapeutic applications has led to the development
of a number of potential agents that can be used to target specific
receptors, all of which can vary greatly in size, lipophilicity,
charge, and target affinity. [37–39] The choice of the optimal
tracer for a specific application is not as simple as just choosing the
agent with the highest targeted affinity since many other factors,
such as vascular permeability, lymphatic drainage, and plasma
clearance, also influence the delivery and retention of targeted
imaging agents. In this study, the uptake distribution of two
promising EGFR targeted tracers, each having considerably
different physical properties were compared in an orthotopic
glioma model in athymic mice. The first tracer was a monoclonal
antibody, cetuximab, which has a high affinity for EGFR with a
KD of 0.1 nM. [40,41] While this would presumably increase the
likelihood of retention, cetuximab is also quite large (152 kDa),
[42] which could hinder its ability to perfuse out of the vasculature
and into the tumor, especially in areas of only partial BBB
breakdown. [21] The second tracer was an anti-EGFR Affibody,
which is considerably smaller in size (6.7 kDa), but also has a
significantly lower affinity for EGFR with a KD of 2.8 nM. [43,44]
The purpose of this study was to determine which of these tracers
would provide inherently better tumor contrast in the context of
fluorescence guided resection of gliomas, wherein the integrity of
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Figure 1. Examination of Affibody and cetuximab distribution over the tumor region. Signal from GFP outlines the tumor (A). H&E stain of
the same tissue slice showing the structural differences between the tumor area and adjacent normal tissue at 8 times magnification (B). Tumor is
outlined in red and area enclosed in the yellow box is shown at 20 times magnification in (C). Fluorescent signal at cetuximab channel shows
significant contrast in much of the tumor, but appears reduced around the edges (D). Fluorescent signal at Affibody channel shows significant
contrast in the tumor and over a broader region of the tumor (E). Fraction of signal from the Affibody channel is shown in (F) and demonstrates
significant deviation in signal from the two channels at the edge and interior of the tumor.
doi:10.1371/journal.pone.0060390.g001
Figure 2. Examination of autofluorescence at both Affibdoy and cetuximab channels over the tumor region Tumor outlined by GFP
signal (A). H&E stain of the same tissue slice showing the structural differences between the tumor area and adjacent normal tissue at 8 times
magnification (B). Area enclosed in the yellow box is shown at 20 times magnification in (C). Autofluorescence at both the cetuximab channel (D) and
the Affibody channel (E) show significant contrast between tumor and non-tumor regions with autofluorescence greatest at the tumor center. No
significant change between tumor interior, tumor edge and non-tumor area is seen for the fraction of signal at the Affibody channel (F).
doi:10.1371/journal.pone.0060390.g002
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the BBB may play a significant role in regulating the perfusion of
the tracers out of the vasculature and into more invasive regions of
the tumor margins. [20–22] This was carried out by labeling the
cetuximab and Affibody with different fluorophores, mixing them
in equal protein concentrations, and injecting them simultaneously
into mice inoculated with an orthotopic human U251 glioma
grown in the left cerebral hemisphere.
On average, nearly equal concentrations of cetuximab and
Affibody were measured in the tumors at 1 h post-tracer injection;
however, an analysis of the spatial distribution of both proteins
demonstrated that there was significantly more Affibody than
cetuximab present in the outer edges of the tumor (roughly twice
as much Affibody as cetuximab was found in the outer 50 um of
the tumor). These are especially interesting results since cetuximab
is known to have a 30 times greater affinity for EGFR than anti-
EGFR Affibody and was seen to remain in the plasma significantly
longer than the Affibody (Fig. 6). Greater time in the blood would
result in greater delivery to the tumor if the extravasation
characteristics of the two proteins were the same. Additionally, a
higher affinity would result in greater tumor retention. It is
believed that the nearly equal concentrations within the tumor is
the result of the greater permeability of the tumor vasculature to
the smaller Affibody than to the larger antibody. In fact, using a
two-tissue compartment model [45] to estimate the expected
relative uptakes of cetuximab to Affibody based on the measured
plasma curves and their theoretical affinities for EGFR, with all
other parameters being equal, the cetuximab concentration was
predicted to be about 4 times higher than that of the Affibody. The
fact that this was not the case suggests that the relative differences
in vascular permeability between the two proteins played a
significant role in their delivery to the tumor regions, particularly
along the tumor edge. It should be noted that the administered
doses are low enough that receptor saturation or competitive
binding between the Affibody and cetuximab is not expected [46].
The presumed differences in vascular permeability between the
Affibody and cetuximab in the tumor interior compared to the
tumor edge are in conjunction with expected differences in the
extent of the breakdown of the BBB in these areas. Breakdown of
the BBB is generally less complete in newly formed regions of the
tumor such as the infiltrative edge [20–22] and the Affibody
protein fraction was most likely higher in these regions owing to
the substantially smaller size of the Affibody (,7 vs. 150 kDa). The
Figure 3. Illustration of procedure used in analysis. Tumor is segmented using GFP signal (A). The outer 50 um edge of the tumor is separated
from the rest of the tumor (B) and the inner portion of the tumor at a distance greater than 125 um from the edge is also separated (C). Scale in (B)
and (C) show fraction of signal at affibody channel.
doi:10.1371/journal.pone.0060390.g003
Figure 4. Comparison of raw fluorescent signals. Raw fluorescent signals from various regions shown at both cetuximab channel (left) and
Affibody channel (right) using box and whisker plots. Signal from injected animals are offset to the left while those from non-injected control animals
are offset to the right with boxes shaded. The central lines are the medians, the edges of the boxes are the 25th and 75th percentiles and individual
data points are plotted as open circles.
doi:10.1371/journal.pone.0060390.g004
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Affibody’s superior delivery to the tumor edge is an important
finding in the context of fluorescence guided surgical resection as it
is the tumor edge that tends to be the most difficult to differentiate
from normal tissue and any tracer that better marks these areas
has a distinct advantage. [12,47] Presumably this would also be
true for isolated glioma cells; however, this was not investigated in
the present study as the orthotopic injection of glioma cells results
in limited tumor cell diffusion making it difficult to examine
isolated groups of cells. The extent to which the relative increased
delivery of Affibody to the tumor edge was the result the Affibody’s
greater vascular extravasation in those regions vs. that which was
do its presumed higher rate of diffusion was not examined here.
However, this is certainly an important question that must be
addressed in future studies considering the clinical situation in
which distance are such that diffusion may not play a significant
role in delivery. [48,49] While there are numerous factors affecting
tracer delivery, the apparent importance of size certainly suggests
that it would be worth examining the performance of other small
targeted proteins. The most obvious is the natural ligand to
EGFR, epidermal growth factor (EGF). EGF is of similar size and
affinity to the Affibody [46,50], however, a primary advantage of
using proteins such as the Affibody or cetuximab is that, unlike
EGF, they do not activate the EGFR signaling pathway, which
could incite tumor growth. [38,51,52] In addition to Affibodies,
there is a large number of other engineered targeted protein
alternatives to full sized antibodies. These include antibody
fragments [39] as well as other non-immunoglobulin derived
proteins such as DARPIins and Anticalins. [39,53] Each of these
classes of proteins should be considered for their potential use as
tracers given the current findings.
The possibility of further modification and optimization of the
Affibody used in the present study should also be considered.
Affibody plasma clearance could be increased through chemical
modification and binding affinity might be enhanced through
improved protein engineering designs. Affibody dimers are
available as imaging agents with a near two fold improvement in
binding affinity due to this bivalency. [43] Despite the fact that
dimers would likely have a more difficult time penetrating areas
with a more intact BBB, their size is still an order of magnitude
below that of antibodies. While the longer plasma half-life of
cetuximab allows for greater tumor uptake it also increases
background signal due to its greater concentration in the blood at
the time of imaging. Any attempts to increase tumor uptake of
Affibodies through extending plasma half-life would have to
consider this tradeoff. Increased time between injection and
imaging may also improve signal-to-background ratios and
certainly should be considered moving forward.
Conclusions
The present study quantifies significant differences in delivery to
the margins of orthotopic human glioma xenografts between two
Figure 5. Comparison of protein concentrations in different
regions of the tumor. Concentrations are calculated as described in
equation (1). The percentage of protein that is Affibody is shown for the
whole tumor, tumor interior and tumor edge using box and whisker
plots. The central lines are the medians, the edges of the boxes are the
25th and 75th percentiles and individual data points are plotted as
open circles.
doi:10.1371/journal.pone.0060390.g005
Figure 6. Comparison of plasma excretion for the two proteins. Plasma excretion data with error bars and bi-exponential curve fits to the
data are shown for cetuximab-IRDye 680RD (left) and Affibody-IRDye 800CW (right). Curve fit equations are also shown where FL is fluorescence
intensity. R-squared values of 0.71 and 0.90 for cetuximab and Affibody fits respectively.
doi:10.1371/journal.pone.0060390.g006
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fluorescently labeled EGFR targeted proteins. While cetuximab
and Affibody had a nearly identical concentrations within the
tumor, the concentration of the cetuximab tracer was more
confined to the interior of the tumor where BBB breakdown is
more complete. The smaller Affibody, with a nearly 30 times lower
affinity and a shorter plasma half life, was found in concentrations
more than double those of cetuximab in the tumor periphery. The
equal or higher abundance of the Affibody compared to
cetuximab, particularly along the edges of the tumors was likely
a result of the incomplete breakdown of the BBB and the size
difference between the two proteins. These results suggest that the
size of a targeting agent (the Affibody is only 6.7 kDa compared to
cetuximab which is 152 kDa) may be a more important parameter
than target affinity when choosing an imaging agent for providing
delineation of tumor boundaries during fluorescence guided
surgery in neurological oncology. This finding is important for
the further investigation and development of fluorescent tracers
that are optimized for marking of the tumor periphery. Small,
fluorescently labeled proteins with high affinity to tumor receptors
show considerable potential for aiding in surgical visualization and
the targeted Affibody examined shows excellent potential for
EGFR positive tumor targeting.
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